Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors
This is an open-label Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of GDC-0919, an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme and help the human immune system attack solid tumor cells more effectively.
Solid Tumor
DRUG: GDC-0919
Percentage of patients with dose-limiting toxicities, 28 days|Number of dose-limiting toxicities, 28 days|Percentage of patients with adverse events, approximately 15 months
Pharmacokinetics: Serum concentrations (Cmax/Steady State), 21 days
This is an open-label Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of GDC-0919, an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme and help the human immune system attack solid tumor cells more effectively.